Dosage forms for low solubility and or low dissolution rate free acid pharmaceutical agents

• US 20050287213A1
• Filed: 06/08/2005
• Published: 12/29/2005
• Est. Priority Date: 06/28/2004
• Status: Abandoned Application

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Li, Sherry Xiuling, Yam, Noymi V., Wong, Patrick S.L.
• Application Number:
  US11/148,679
• Publication Number:
  US 20050287213A1
• Time in Patent Office: Days
• US Class Current: 424/473
• CPC Class Codes: A61K 9/0004 Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Abstract

An osmotic controlled release dosage form is described comprising a core comprising a first drug composition, wherein the first drug composition comprises topiramate and/or its pharmaceutically acceptable salt; a semi-permeable wall surrounding the core; and an exit orifice through the semi-permeable wall for releasing the first drug composition from the dosage form over a prolonged period of time.

Claims

1. An osmotic controlled release dosage form comprising a drug composition comprising:

a low solubility and/or low dissolution rate free acid pharmaceutical agent, and

a pharmaceutically acceptable salt thereof.

2. The osmotic controlled release dosage form of claim 1, wherein the drug composition comprises acyclovir, aspirin, azathioprine, cefoxitin, furosemide, ganciclovir, glipizide, ibuprofen, ketoprofen, mefenamic acid, methotrexate, omeprazole, phenobarbitol, topiramate, valproic acid, or combinations thereof.

3. The osmotic controlled release dosage form of claim 2, wherein the drug composition comprises topiramate.

4. The osmotic controlled release dosage form of claim 1, with the proviso that the drug composition is substantially free from solubilizing agents.

5. An osmotic controlled release dosage form comprising

a core comprising a first drug composition, wherein the first drug composition comprises a low solubility and/or low dissolution rate free acid pharmaceutical agent and/or its pharmaceutically acceptable salt;

a semi-permeable wall surrounding the core; and

an exit orifice through the semi-permeable wall for releasing the first drug composition from the dosage form over a prolonged period of time

6. The osmotic controlled release dosage form of claim 5, wherein the weight ratio of low solubility and/or low dissolution rate free acid pharmaceutical agent to its pharmaceutically acceptable salt in the first drug composition is in the range of from about 0.25 to about 2.0

7. The osmotic controlled release dosage form of claim 6, wherein the weight ratio of low solubility and/or low dissolution rate free acid pharmaceutical agent to its pharmaceutically acceptable salt in the first drug composition is in the range of from about 0.3 to about 1.5

8. The osmotic controlled release dosage form of claim 7, wherein the weight ratio of low solubility and/or low dissolution rate free acid pharmaceutical agent to its pharmaceutically acceptable salt in the first drug composition is in the range of from about 0.5 to about 1.0.

9. An osmotic controlled release dosage form comprising

a core comprising

a first drug composition,

a second drug composition and

a push layer,

wherein the first and second drug composition each comprise a low solubility and/or low dissolution rate free acid pharmaceutical agent and/or its pharmaceutically acceptable salt;

a semi-permeable wall surrounding the core; and

an exit orifice through the semi-permeable wall for releasing the first and second drug compositions from the dosage form over a prolonged period of time.

10. The osmotic controlled release dosage form of claim 9, wherein the first drug composition comprises low solubility and/or low dissolution rate free acid pharmaceutical agent and is substantially free from its pharmaceutically acceptable salt, and the second drug composition comprises the pharmaceutically acceptable salt and is substantially free from the low solubility and/or low dissolution rate free acid pharmaceutical agent.

11. The osmotic controlled release dosage form of claim 9, wherein the first drug composition comprises low solubility and/or low dissolution rate free acid pharmaceutical agent and its pharmaceutically acceptable salt in a weight ratio of about 0.5 to about 5.0 acid:

salt

12. The osmotic controlled release dosage form of claim 9, wherein the second drug composition comprises the low solubility and/or low dissolution rate free acid pharmaceutical agent and its pharmaceutically acceptable salt in a weight ratio of about 0.15 to about 2.0 acid:

salt.